Endo Dives Deeper Into Devices With AMS Acquisition
Executive Summary
With its $2.9 billion acquisition of American Medical Systems, Endo Pharmaceutical Holdings is further diversifying its specialty pharma portfolio into devices and services.
You may also be interested in...
The New World Of Device Venture Investing: Same As The Old World?
At Elsevier Business Intelligence's February IN3 West conference, a panel of leading device venture investors, who remain committed to and are actively doing deals in medtech, discussed how the recent recession has affected device investing and how much, if at all, that world has changed as a result.
Valeant's Hostile Bid For Cephalon
Valeant's hostile bid for Cephalon is a rejection of the traditional high risk, high reward R&D model employed by biopharma.
The New World Of Device Venture Investing: Same As The Old World?
At Elsevier Business Intelligence's February IN3 West conference, a panel of leading device venture investors, who remain committed to and are actively doing deals in medtech, discussed how the recent recession has affected device investing and how much, if at all, that world has changed as a result.